Fulcrum Therapeutics (FULC) Accounts Payables (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accounts Payables data on file, last reported at $2.4 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 62.57% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 62.57% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 36.77% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.4 million, up from $1.6 million in the prior quarter.
• Over the last five years, Accounts Payables for FULC reached as high as $6.0 million in Q1 2022 and fell as low as $1.2 million in Q4 2024.
• Historically, Accounts Payables has averaged $3.2 million across 5 years, with a median of $3.6 million in 2023.
• Across the five-year window, Accounts Payables tumbled 60.93% in 2025 and surged 62.57% in 2026, its largest moves.
• Year by year, Accounts Payables stood at $3.6 million in 2022, then retreated by 24.22% to $2.8 million in 2023, then sank by 57.78% to $1.2 million in 2024, then jumped by 36.77% to $1.6 million in 2025, then surged by 53.89% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $2.4 million in Q1 2026, $1.6 million in Q4 2025, and $2.9 million in Q3 2025.